Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.
Michael W BaughnZe'ev MelamedJone López-ErauskinMelinda S BeccariKaren K LingAamir R ZuberiMaximilliano PresaElena Gonzalo-GilRoy MaimonSonia Vazquez-SanchezSom ChaturvediMariana Bravo-HernándezVanessa TaupinStephen MooreJonathan W ArtatesEitan AcksI Sandra NdayambajeAna Rita Agra de Almeida QuadrosPaayman Jafar-NejadFrank RigoC Frank BennettCathleen LutzClotilde Lagier-TourenneDon W ClevelandPublished in: Science (New York, N.Y.) (2023)
Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration. We found that TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in STMN2 pre-mRNA. Targeting dCasRx or antisense oligonucleotides (ASOs) suppressed cryptic splicing, which restored axonal regeneration and stathmin-2-dependent lysosome trafficking in TDP-43-deficient human motor neurons. In mice that were gene-edited to contain human STMN2 cryptic splice-polyadenylation sequences, ASO injection into cerebral spinal fluid successfully corrected Stmn2 pre-mRNA misprocessing and restored stathmin-2 expression levels independently of TDP-43 binding.
Keyphrases
- amyotrophic lateral sclerosis
- endothelial cells
- stem cells
- binding protein
- spinal cord
- poor prognosis
- type diabetes
- crispr cas
- pluripotent stem cells
- induced pluripotent stem cells
- metabolic syndrome
- small molecule
- copy number
- genome wide
- adipose tissue
- dna methylation
- transcription factor
- brain injury
- cerebral ischemia
- long non coding rna
- cancer therapy
- genetic diversity
- high fat diet induced